News Releases

CAMBRIDGE, Mass. — May 5, 2021  — Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical,

Results Validate  In Vivo  Liver DNA Base Editing as a Once-and-Done Approach to Treat Coronary Heart Disease by Lowering of LDL Cholesterol and PCSK9 Protein Levels   Company Selects VERVE-101 as Lead Program to Treat Heterozygous Familial Hypercholesterolemia CAMBRIDGE, Mass.

Proceeds Support Advancement of VERVE-101 toward Clinical Initiation in 2022 CAMBRIDGE, Mass. — January 19, 2021  —  Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B

CAMBRIDGE, Mass. — January 6, 2021 —  Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present a company overview during the 39 th  Annual J.P.